Demyelinating Polyradiculoneuropathy in Chronic Lymphocytic Leukemia: A Case Report on BTKis versus Venetoclax-Rituximab
Abstract
:1. Introduction
2. Detailed Case Description
3. Discussion
4. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- The Surveillance E, and End Results (SEER) Program of the National Cancer Institute. Cancer Stat Facts: Leukemia—Chronic Lymphocytic Leukemia (CLL). 2021. Available online: https://seer.cancer.gov/statfacts/html/clyl.html (accessed on 16 August 2023).
- Vitale, C.; Boccellato, E.; Comba, L.; Jones, R.; Perutelli, F.; Griggio, V.; Coscia, M. Impact of Immune Parameters and Immune Dysfunctions on the Prognosis of Patients with Chronic Lymphocytic Leukemia. Cancers 2021, 13, 3856. [Google Scholar] [CrossRef] [PubMed]
- Hodgson, K.; Ferrer, G.; Montserrat, E.; Moreno, C. Chronic lymphocytic leukemia and autoimmunity: A systematic review. Haematologica 2011, 96, 752–761. [Google Scholar] [CrossRef] [PubMed]
- Visentin, A.; Imbergamo, S.; Gurrieri, C.; Frezzato, F.; Trimarco, V.; Martini, V.; Severin, F.; Raggi, F.; Scomazzon, E.; Facco, M.; et al. Major infections, secondary cancers and autoimmune diseases occur in different clinical subsets of chronic lymphocytic leukaemia patients. Eur. J. Cancer 2017, 72, 103–111. [Google Scholar] [CrossRef] [PubMed]
- Briani, C.; Visentin, A.; Salvalaggio, A.; Imbergamo, S.; Piazza, F.; Cacciavillani, M.; Campagnolo, M.; Frezzato, F.; Semenzato, G.; Trentin, L. Peripheral neuropathies in chronic lymphocytic leukemia: A single center experience on 816 patients. Haematologica 2017, 102, e140–e143. [Google Scholar] [CrossRef] [PubMed]
- Lewis, D.; Osman, C.; Allen, D.; Pinto, A.A.; Duncombe, A.; A Katifi, H. Refractory CIDP with chronic lymphocytic leukaemia responding to chemoimmunotherapy. Pract. Neurol. 2020, 21, 143–146. [Google Scholar] [CrossRef] [PubMed]
- Lad, D.P.; Varma, S.; Varma, N.; Sachdeva, M.U.S.; Bose, P.; Malhotra, P. Regulatory T-cell and T-helper 17 balance in chronic lymphocytic leukemia progression and autoimmune cytopenias. Leuk. Lymphoma 2015, 56, 2424–2428. [Google Scholar] [CrossRef] [PubMed]
- Ibrutinib [Package Insert]; Janssen Biotech, Inc.: Horsham, PA, USA, 2023.
- Castellani, F.; Visentin, A.; Campagnolo, M.; Salvalaggio, A.; Cacciavillani, M.; Candiotto, C.; Bertorelle, R.; Trentin, L.; Briani, C. The Bruton tyrosine kinase inhibitor ibrutinib improves anti-MAG antibody polyneuropathy. Neurol.-Neuroimmunol. Neuroinflamm. 2020, 7, e720. [Google Scholar] [CrossRef]
- Castellani, F.; Visentin, A.; Schirinzi, E.; Salvalaggio, A.; Cacciavillani, M.; Candiotto, C.; Baratè, C.; Cellini, A.; Bertorelle, R.; Siciliano, G.; et al. Mutational Profile in 75 Patients with Anti–Myelin-Associated Glycoprotein Neuropathy: Clinical and Hematologic Therapy Response and Hints on New Therapeutic Targets. Neurol.-Neuroimmunol. Neuroinflamm. 2023, 10, e200122. [Google Scholar] [CrossRef]
- Shaikh, H.; Khattab, A.; Faisal, M.S.; Chilkulwar, A.; Albrethsen, M.; Sadashiv, S.; Fazal, S. Case series of unique adverse events related to the use of ibrutinib in patients with B-cell malignancies—A single institution experience and a review of literature. J. Oncol. Pharm. Pract. 2018, 25, 1265–1270. [Google Scholar] [CrossRef]
- Wanner, D.; Bohn, J.-P.; Rudzki, J.; Stockhammer, G.; Steurer, M. Autoimmune myelitis in a CLL patient undergoing treatment with ibrutinib. Ann. Hematol. 2019, 98, 205–207. [Google Scholar] [CrossRef]
- Mato, A.R.; Islam, P.; Daniel, C.; Strelec, L.; Kaye, A.H.; Brooks, S.; Ganetsky, A.; Nasta, S.; Porter, D.L.; Svoboda, J.; et al. Ibrutinib-induced pneumonitis in patients with chronic lymphocytic leukemia. Blood 2016, 127, 1064–1067. [Google Scholar] [CrossRef] [PubMed]
- Venetoclax [Package Insert]; Genentech: South San Francisco, CA, USA; AbbVie: North Chicago, IL, USA, 2022.
- Anderson, M.A.; Deng, J.; Seymour, J.F.; Tam, C.; Kim, S.Y.; Fein, J.; Yu, L.; Brown, J.R.; Westerman, D.; Si, E.G.; et al. The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism. Blood 2016, 127, 3215–3224. [Google Scholar] [CrossRef]
- Jones, J.A.; Mato, A.R.; Wierda, W.G.; Davids, M.S.; Choi, M.; Cheson, B.D.; Furman, R.R.; Lamanna, N.; Barr, P.M.; Zhou, L.; et al. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: An interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol. 2018, 19, 65–75. [Google Scholar] [CrossRef] [PubMed]
- Briani, C.; Visentin, A.; Castellani, F.; Cacciavillani, M.; Trentin, L. The BCL2 Inhibitor Venetoclax Plus Rituximab Is Active in MYD88 Wild-Type Polyneuropathy with Anti-MAG Antibodies. Neurol.-Neuroimmunol. Neuroinflamm. 2022, 9, e1181. [Google Scholar] [CrossRef] [PubMed]
- Visentin, A.; Bonaldi, L.; Rigolin, G.M.; Mauro, F.R.; Martines, A.; Frezzato, F.; Pravato, S.; Gargarella, L.R.; Bardi, M.A.; Cavallari, M.; et al. The complex karyotype landscape in chronic lymphocytic leukemia allows the refinement of the risk of Richter syndrome transformation. Haematologica 2022, 107, 868–876. [Google Scholar] [CrossRef] [PubMed]
- Hughes, R.; Bensa, S.; Willison, H.; Bergh, P.V.D.; Comi, G.; Illa, I.; Nobile-Orazio, E.; Van Doorn, P.; Dalakas, M.; Bojar, M.; et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann. Neurol. 2001, 50, 195–201. [Google Scholar] [CrossRef] [PubMed]
- Miller, F.W.; Hess, E.V.; Clauw, D.J.; Hertzman, P.A.; Pincus, T.; Silver, R.M.; Mayes, M.D.; Varga, J.; Medsger, T.A.; Love, L.A. Approaches for identifying and defining environmentally associated rheumatic disorders. Arthritis Rheumatol. 2001, 43, 241–249. [Google Scholar] [CrossRef]
- Munir, T.; Brown, J.R.; O’Brien, S.; Barrientos, J.C.; Barr, P.M.; Reddy, N.M.; Coutre, S.; Tam, C.S.; Mulligan, S.P.; Jaeger, U.; et al. Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am. J. Hematol. 2019, 94, 1353–1363. [Google Scholar] [CrossRef]
- Burger, J.A.; Barr, P.M.; Robak, T.; Owen, C.; Ghia, P.; Tedeschi, A.; Bairey, O.; Hillmen, P.; Coutre, S.E.; Devereux, S.; et al. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia 2020, 34, 787–798. [Google Scholar] [CrossRef]
- Woyach, J.A.; Ruppert, A.S.; Heerema, N.A.; Zhao, W.; Booth, A.M.; Ding, W.; Bartlett, N.L.; Brander, D.M.; Barr, P.M.; Rogers, K.A.; et al. Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. N. Engl. J. Med. 2018, 379, 2517–2528. [Google Scholar] [CrossRef]
- Shanafelt, T.D.; Wang, X.V.; Kay, N.E.; Hanson, C.A.; O’brien, S.; Barrientos, J.; Jelinek, D.F.; Braggio, E.; Leis, J.F.; Zhang, C.C.; et al. Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia. N. Engl. J. Med. 2019, 381, 432–443. [Google Scholar] [CrossRef]
- Byrd, J.C.; Hillmen, P.; Ghia, P.; Kater, A.P.; Chanan-Khan, A.; Furman, R.R.; O’Brien, S.; Yenerel, M.N.; Illés, A.; Kay, N.; et al. Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial. J. Clin. Oncol. 2021, 39, 3441–3452. [Google Scholar] [CrossRef] [PubMed]
- Brown, J.R.; Eichhorst, B.; Hillmen, P.; Jurczak, W.; Kaźmierczak, M.; Lamanna, N.; O’brien, S.M.; Tam, C.S.; Qiu, L.; Zhou, K.; et al. Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia. N. Engl. J. Med. 2023, 388, 319–332. [Google Scholar] [CrossRef] [PubMed]
- Broglio, L.; Lauria, G. Worsening after rituximab treatment in anti-mag neuropathy. Muscle Nerve 2005, 32, 378–379. [Google Scholar] [CrossRef] [PubMed]
- Stork, A.C.J.; Notermans, N.C.; Vrancken, A.F.J.E.; Cornblath, D.R.; van der Pol, W.-L. Rapid worsening of IgM anti-MAG demyelinating polyneuropathy during rituximab treatment. J. Peripher. Nerv. Syst. 2013, 18, 189–191. [Google Scholar] [CrossRef] [PubMed]
- Sala, E.; Robert-Varvat, F.; Paul, S.; Camdessanché, J.-P.; Antoine, J.-C. Acute neurological worsening after Rituximab treatment in patients with anti-MAG neuropathy. J. Neurol. Sci. 2014, 345, 224–227. [Google Scholar] [CrossRef] [PubMed]
- Benedetti, L.; Franciotta, D.; Vigo, T.; Grandis, M.; Fiorina, E.; Ghiglione, E.; Roccatagliata, L.; Mancardi, G.L.; Uccelli, A.; Schenone, A. Relapses After Treatment with Rituximab in a Patient with Multiple Sclerosis and Anti–Myelin-Associated Glycoprotein Polyneuropathy. Arch. Neurol. 2007, 64, 1531–1533. [Google Scholar] [CrossRef]
- Noronha, V.; Fynan, T.M.; Duffy, T. Flare in Neuropathy Following Rituximab Therapy for Waldenstrom’s Macroglobulinemia. J. Clin. Oncol. 2006, 24, e3. [Google Scholar] [CrossRef]
- Gironi, M.; Saresella, M.; Ceresa, L.; Calvo, M.; Ferrante, P.; Merli, F.; Nemni, R. Clinical and immunological worsening in a patient affected with Waldenstrom mac-roglobulinemia and anti-mag neuropathy after treatment with rituximab. Haematologica 2006, 91 (Suppl. S6), e51–e52. [Google Scholar]
- Velasco, R.; Alberti, P.; Bruna, J.; Psimaras, D.; Argyriou, A.A. Bortezomib and other proteosome inhibitors—Induced peripheral neurotoxicity: From pathogenesis to treatment. J. Peripher. Nerv. Syst. 2019, 24, S52–S62. [Google Scholar] [CrossRef]
- Briani, C.; Visentin, A.; Cerri, F.; Quattrini, A. From pathogenesis to personalized treatments of neuropathies in hematological malignancies. J. Peripher. Nerv. Syst. 2020, 25, 212–221. [Google Scholar] [CrossRef] [PubMed]
- Riva, M.; Lessi, F.; Berno, T.; Visentin, A.; Campagnolo, M.; Semenzato, G.; Adami, F.; Briani, C. Bortezomib-based regimens in patients with POEMS syndrome: A case series in newly diagnosed and relapsed patients. Leuk. Lymphoma 2019, 60, 2067–2070. [Google Scholar] [CrossRef] [PubMed]
- Mhibik, M.; Wiestner, A.; Sun, C. Harnessing the Effects of BTKi on T Cells for Effective Immunotherapy against CLL. Int. J. Mol. Sci. 2019, 21, 68. [Google Scholar] [CrossRef] [PubMed]
- Long, M.; Beckwith, K.; Do, P.; Mundy, B.L.; Gordon, A.; Lehman, A.M.; Maddocks, K.J.; Cheney, C.; Jones, J.A.; Flynn, J.M.; et al. Ibrutinib treatment improves T cell number and function in CLL patients. J. Clin. Investig. 2017, 127, 3052–3064. [Google Scholar] [CrossRef]
- Puzzolo, M.C.; Del Giudice, I.; Peragine, N.; Mariglia, P.; De Propris, M.S.; Cappelli, L.V.; Trentin, L.; Reda, G.; Cuneo, A.; Molica, S.; et al. TH2/TH1 Shift Under Ibrutinib Treatment in Chronic Lymphocytic Leukemia. Front Oncol. 2021, 11, 637186. [Google Scholar] [CrossRef]
- De Weerdt, I.; Hofland, T.; de Boer, R.; Dobber, J.A.; Dubois, J.; van Nieuwenhuize, D.; Mobasher, M.; de Boer, F.; Hoogendoorn, M.; Velders, G.A.; et al. Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment. Blood Adv. 2019, 3, 2642–2652. [Google Scholar] [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Cellini, A.; Visentin, A.; Salvalaggio, A.; Cacciavillani, M.; Ferrari, S.; Briani, C. Demyelinating Polyradiculoneuropathy in Chronic Lymphocytic Leukemia: A Case Report on BTKis versus Venetoclax-Rituximab. Hemato 2024, 5, 19-25. https://doi.org/10.3390/hemato5010003
Cellini A, Visentin A, Salvalaggio A, Cacciavillani M, Ferrari S, Briani C. Demyelinating Polyradiculoneuropathy in Chronic Lymphocytic Leukemia: A Case Report on BTKis versus Venetoclax-Rituximab. Hemato. 2024; 5(1):19-25. https://doi.org/10.3390/hemato5010003
Chicago/Turabian StyleCellini, Alessandro, Andrea Visentin, Alessandro Salvalaggio, Mario Cacciavillani, Sergio Ferrari, and Chiara Briani. 2024. "Demyelinating Polyradiculoneuropathy in Chronic Lymphocytic Leukemia: A Case Report on BTKis versus Venetoclax-Rituximab" Hemato 5, no. 1: 19-25. https://doi.org/10.3390/hemato5010003